New Non-Destructive Inspection, Blister Recovery and Packaging Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New Non-Destructive Inspection, Blister Recovery and Packaging Technologies launched by Sepha Ltd.

Three new products aimed at meeting the changing demands of global pharma-companies are being introduced by the pharmaceutical packaging equipment specialist, Sepha Ltd.

The first machine, BottleScan, is the world’s first tool-less, non-destructive leak detection instrument for testing multiple induction-sealed bottles simultaneously.  It incorporates force decay technology to test induction-sealed bottles for holes and weak seals without destroying the contents. Ahead of itsEuropean debut, BottleScan has already attracted orders from Asian and North American customers.

Press Out Universal Mini is a low volume, rapid product change over deblistering unit that enables product to be recovered from all blister pack types, particularlychild resistant,peel-able and senior-friendly packs. The unit has been developed to reflect changes in the pharmaceutical manufacturing market, where manufacturers are focusing on shorter runs of more bespoke, high value drugs in child resistant or senior-friendly blister packs.

Finally, EZ MedPakextends Sepha's 'EZ' range of low volume, package development unitsinto the wider medical packaging market. It is aimed specifically at medical device and packaging development teams who want to take control of their own pack designs and develop bespoke packs for small devices and pre-filled syringes.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here